RXi Pharmaceuticals Corporation (RXII) Shares Down 0%
RXi Pharmaceuticals Corporation (NASDAQ:RXII)’s share price was down 0% during trading on Thursday . The stock traded as low as $0.50 and last traded at $0.51. Approximately 506,333 shares traded hands during trading, an increase of 3% from the average daily volume of 490,733 shares. The stock had previously closed at $0.51.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter in the prior year, the firm posted ($0.34) EPS. analysts forecast that RXi Pharmaceuticals Corporation will post -0.74 earnings per share for the current fiscal year.
In other RXi Pharmaceuticals Corporation news, insider Alexey Eliseev sold 176,800 shares of RXi Pharmaceuticals Corporation stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $0.54, for a total transaction of $95,472.00. Following the transaction, the insider now owns 1,100,931 shares of the company’s stock, valued at approximately $594,502.74. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.71% of the stock is owned by company insiders.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.